UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000009970
Receipt No. R000011602
Scientific Title A Factorial Randomized Controlled Trial of Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients: CANDLE-KIT trial
Date of disclosure of the study information 2013/02/06
Last modified on 2019/02/10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A Factorial Randomized Controlled Trial of Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients: CANDLE-KIT trial
Acronym Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients: CANDLE-KIT trial
Scientific Title A Factorial Randomized Controlled Trial of Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients: CANDLE-KIT trial
Scientific Title:Acronym Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients: CANDLE-KIT trial
Region
Japan

Condition
Condition Kidney transplantation
Classification by specialty
Nephrology Urology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the effect of anemia correction and vitamin D supplementation on allograft kidney function
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase IV

Assessment
Primary outcomes Change in estimated glomerular filtration rate
Key secondary outcomes - Urine markers of kidney injury at 6 months
1) L-FABP
2) NGAL
3) TGF-beta
4) Protein-creatinine ratio
- The dose of epoetin beta pegol required to maintain the target hemoglobin level
- C-reactive protein
- Change in blood pressure
- Cardiac biomarkers
1) BNP
2) Cardiac troponin-T
- left-ventricular mass index
- Biopsy-proven acute cellular rejection
- Bone-turnover markers
1) 1-84 PTH
2) Bone-type alkaline phosphatase
3) tartrate-resistant acid phosphatase 5b (TRACP-5b)
- Bone mineral density of lumber spine and femoral neck.
- Hypercalcemia (Corrected calcium >=11 mg/dL)
- Event-free survival for the following endpoints
1) Renal composite endpoint (50% increase in serum creatinine, subsequent transplantation, and reinitiation of dialysis)
2) Admission-required cardiovascular events (myocardial infarction, angina, congestive heart failure, stroke, and peripheral artery disease)
3) All-cause death
4) Cancer development or recurrence
5) Infections requiring hospitalization (e.g., Polyomavirus-associated nephropathy, tuberculosis, Pneumocystis carinii pneumonia, cytomegalovirus infection, herpes zoster, bacterial pneumonia)

Base
Study type Interventional

Study design
Basic design Factorial
Randomization Randomized
Randomization unit Individual
Blinding Open -but assessor(s) are blinded
Control Active
Stratification YES
Dynamic allocation NO
Institution consideration Institution is considered as a block.
Blocking YES
Concealment Central registration

Intervention
No. of arms 4
Purpose of intervention Treatment
Type of intervention
Medicine Food
Interventions/Control_1 Conventional anemia management (Target Hb >=9.5 and <10.5 g/dL) with cholecalciferol (1,000 IU/day)
Interventions/Control_2 Conventional anemia management (Target Hb >=9.5 and <10.5 g/dL) without cholecalciferol
Interventions/Control_3 Aggressive anemia correction (Target Hb >=12.5 and <13.5 g/dL) with cholecalciferol (1,000 IU/day)
Interventions/Control_4 Aggressive anemia correction (Target Hb >=12.5 and <13.5 g/dL) without cholecalciferol
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1) >=15 and <60 ml/min per 1.73 m2 of estimated glomerular filtration rate
2) Transplanted allograft kidney at least 1 year before
3) <10.5 g/dL of Hb without iron deficiency (serum ferritin level >=50 ng/ml) or on erythropoiesis stimulating agents treatment regardless of iron status
4) With written informed consent
Key exclusion criteria 1) On anticancer treatment
2) History of ischemic stroke or transient ischemic attack
3) Corrected serum calcium >=10.5 mg/dL
4) HIV virus infection
5) Anticipated refractory hypertension by using epoetin beta pegol
6) In pregnancy and lactation
7) Current use of native vitamin D supplement
8) Patients ineligible according to the investigator's judgement
Target sample size 272

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takayuki Hamano
Organization Osaka University Graduate School of Medicine
Division name Department of Comprehensive Kidney Disease Research
Zip code
Address 2-2, Yamada-oka, Suita, Osaka 565-0871, Japan
TEL 06-6879-3857
Email tsubakihara@kid.med.osaka-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yoshitsugu Obi
Organization Osaka University Graduate School of Medicine
Division name Department of Nephrology
Zip code
Address 2-2, Yamada-oka, Suita, Osaka 565-0871, Japan
TEL 06-6879-3857
Homepage URL
Email y-obi@kid.med.osaka-u.ac.jp

Sponsor
Institute CANDLE-KIT Trial Study Group
Institute
Department

Funding Source
Organization Chugai pharmaceutical Co. Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor MID Co. Ltd.
Roche diagnostics
Name of secondary funder(s) Japan Society for the Promotion of Science
The Kidney Foundation, Japan

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs YES
Study ID_1 NCT01817699
Org. issuing International ID_1 ClinicalTrials.gov
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 市立札幌病院(北海道)、北海道大学病院(北海道)、秋田大学医学部附属病院(秋田県)、仙台社会保険病院(宮城県)、新潟大学(新潟)、自治医科大学(栃木県)、国立水戸医療センター(茨城)、新潟大学(新潟県)、千葉東病院(千葉県)、虎の門病院(東京都)、東邦大学医療センター大森病院(東京都)、東京女子医科大学病院(東京都)、北里大学病院(神奈川県)、聖マリアンナ医科大学病院(神奈川県)、藤田保健衛生大学(愛知県)、名古屋第二赤十字病院(愛知県)、社会保険中京病院(愛知県)、サンシャインM&Dクリニック(岐阜県)、岐阜大学医学部附属病院(岐阜県)、奈良県立医科大学附属病院(奈良県)、大阪市立大学医学部附属病院(大阪府)、大阪府立急性期・総合医療センター(大阪府)、蒼龍会井上病院(大阪府)、愛仁会高槻病院(大阪府)、大阪船員保険病院(大阪府)、伊藤クリニック(大阪府)、日本赤十字社和歌山医療センター(和歌山県)、兵庫県立西宮病院(兵庫県)、岡山医療センター(岡山県)、香川大学(香川県)、熊本赤十字病院(熊本県)、九州大学病院(福岡県)、豊見城中央病院(沖縄県)

Other administrative information
Date of disclosure of the study information
2013 Year 02 Month 06 Day

Related information
URL releasing protocol http://clinicaltrials.gov/ct2/show/NCT01817699?term=NCT01817699&rank=1
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2013 Year 02 Month 05 Day
Date of IRB
Anticipated trial start date
2013 Year 04 Month 15 Day
Last follow-up date
2018 Year 12 Month 01 Day
Date of closure to data entry
2019 Year 02 Month 28 Day
Date trial data considered complete
2019 Year 03 Month 10 Day
Date analysis concluded
2019 Year 03 Month 31 Day

Other
Other related information

Management information
Registered date
2013 Year 02 Month 05 Day
Last modified on
2019 Year 02 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011602

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.